Candriam S.C.A. Iveric Bio, Inc. Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$26.24 - $39.63 $16.1 Million - $24.4 Million	-615,098 Reduced 66.07%	315,832 $12.4 Million
Q1 2023 May 12, 2023	SELL	$18.67 - $24.56 $3.83 Million - $5.03 Million	-204,902 Reduced 18.04%	930,930 $22.6 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $9.19 Million - $12.8 Million	533,000 Added 88.42%	1,135,832 $24.3 Million
Q3 2022 Nov 10, 2022	SELL	$9.4 - $18.59 $8.12 Million - $16.1 Million	-863,739 Reduced 58.9%	602,832 $10.8 Million
Q2 2022 Aug 03, 2022	BUY	$9.12 - $18.9 $4.43 Million - $9.18 Million	485,620 Added 49.51%	1,466,571 $14.1 Million

Q1 2022 May 13, 2022	SELL	$12.15 - $16.83 $2.85 Million - $3.94 Million	-234,321 Reduced 19.28%	980,951 $16.5 Million
Q3 2021 Nov 09, 2021	BUY	$7.07 - $17.5 $3.82 Million - $9.44 Million	539,697 Added 79.89%	1,215,272 $19.7 Million
Q2 2021 Jul 20, 2021	BUY	$5.69 - $7.17 $3.84 Million - $4.84 Million	675,575 New	675,575 $4.26 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.